Coronary artery disease with dyslipidemia
Conditions
Interventions
EISODE is a 12-months, prospective, randomized, open, blinded-endpoint (PROBE) study. Patients with coronary artery disease and increased LDL-cholesterol are enrolled and anti-dyslipidemic medications
100mg/dL), antidyslipidemic drugs other than statins are prescribed to achieve the target level.
After a 4-week run-in period, baseline evaluations are performed. Then, patients are assigned to receiv
100mg/dL), antidyslipidemic drugs other than statins are prescribed to achieve the target level.
Sponsors
Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients are eligible for inclusion in the study if (1) they are >=20 years of age; (2) have coronary artery disease (previous acute coronary syndrome or revascularization >3 months before informed consent, or stable angina pectoris with significant angiographical coronary stenosis (>=75%); and (3) have elevated LDL-cholesterol (>=100 mg/dL) or receive antidyslipidemic treatment.
Exclusion criteria
Exclusion criteria: Severe heart failure (ejection fraction <30% or NYHA III or IV), malignant neoplasm, active inflammatory disease, familial hyperlipidemia, chronic hemodialysis, pregnancy, contra-indication to pitavastatin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in brachial-ankle PWV (baPWV), AI, and central aortic pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in lipid profile, malondialdehyde-modified (MDA)-LDL, apolipoprotein B, apolipoprotein A-I | — |
Countries
Japan
Contacts
Public ContactYasuaki Dohi
Nagoya City University Graduate School of Medical Sciences Cardio-Renal Medicine and Hypertension
Outcome results
None listed